MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 10 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Abstract OT3-05-06: EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), intermediate-risk, early breast cancer (EBC)
J. O’Shaughnessy, Emilio Alba, Aditya Bardia, Susan Dent, Véronique Dièras, Gabriel N. Hortobágyi +8 more
2018· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
2
citations
affunlabeled
Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A
Eva Ciruelos, Florence Lerebours, Hope S. Rugo, Manuel Ruíz‐Borrego, Pamela Drullinsky, Aleix Prat +9 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
2
citations
afffundaboutunlabeled
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer
Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, Jan‐Willem Henning, Swati Kulkarni, Nadia Califaretti +10 more
2025· article· en· Breast Cancer Research and Treatment· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
2
citations
aboutno affunlabeled
Abstract P1-18-29: Male patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving palbociclib in the real-world: patient characteristics, treatment patterns, and outcomes from the POLARIS study
Joanne L. Blum, Caroline DiCristo, David J. Gordon, Meghan Karuturi, D. Oubre, Erin Jepsen +5 more
2022· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
1
citations
affunlabeled
Abstract PR12: Targeting CDK7/9 in basal pancreatic cancer
Sita Kugel, Nithya Kartha, Jessica E. Gianopulos, Z. Schrank, Sarah M. Cavender, Stephanie Dobersch +4 more
2024· article· en· Cancer Research· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
1
citations
venueno affunlabeled
Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110
Alberto Alvarado‐Miranda, Fernando Lara-Medina, Wendy Munoz-Moñtano, Juan W. Zinser-Sierra, Paula Anel Cabrera Galeana, Cynthia Villarreal‐Garza +5 more
2024· erratum· en· Current Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · metaepi_narrow
1
citations
affunlabeled
Abstract PO2-20-04: TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancer
Claudine Isaacs, Katarzyna J. Jerzak, John Hilton, José Luiz Guimarães, Rachel Layman, Dongrui R. Lu +5 more
2024· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
1
citations
← previousnext →

How this was built: Screen · Findings · About